Cinzia Ferri

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8043064/publications.pdf

Version: 2024-02-01

430874 552781 1,639 26 18 26 h-index citations g-index papers 28 28 28 2132 times ranked citing authors docs citations all docs

#	Article	IF	CITATIONS
1	Treatment with IFB-088 Improves Neuropathy in CMT1A and CMT1B Mice. Molecular Neurobiology, 2022, 59, 4159-4178.	4.0	14
2	Phosphorylation of eIF2α Promotes Schwann Cell Differentiation and Myelination in CMT1B Mice with Activated UPR. Journal of Neuroscience, 2020, 40, 8174-8187.	3. 6	14
3	Schwann cells ER-associated degradation contributes to myelin maintenance in adult nerves and limits demyelination in CMT1B mice. PLoS Genetics, 2019, 15, e1008069.	3.5	18
4	Enhanced axonal neuregulin-1 type-III signaling ameliorates neurophysiology and hypomyelination in a Charcot–Marie–Tooth type 1B mouse model. Human Molecular Genetics, 2019, 28, 992-1006.	2.9	24
5	Sustained Expression of Negative Regulators of Myelination Protects Schwann Cells from Dysmyelination in a Charcot–Marie–Tooth 1B Mouse Model. Journal of Neuroscience, 2018, 38, 4275-4287.	3.6	25
6	Electron Microscopy for the Analysis of Peripheral Nerve Myelin. Methods in Molecular Biology, 2018, 1791, 3-13.	0.9	7
7	Laminin 211 inhibits protein kinase A in Schwann cells to modulate neuregulin 1 type III-driven myelination. PLoS Biology, 2017, 15, e2001408.	5.6	44
8	Perlecan is recruited by dystroglycan to nodes of Ranvier and binds the clustering molecule gliomedin. Journal of Cell Biology, 2015, 208, 313-329.	5 . 2	37
9	Lack of Sterol Regulatory Element Binding Factor-1c Imposes Glial Fatty Acid Utilization Leading to Peripheral Neuropathy. Cell Metabolism, 2015, 21, 571-583.	16.2	51
10	MpzR98C arrests Schwann cell development in a mouse model of early-onset Charcot–Marie–Tooth disease type 1B. Brain, 2012, 135, 2032-2047.	7.6	61
11	POS63del impedes the arrival of wild-type PO glycoprotein to myelin in CMT1B mice. Human Molecular Genetics, 2011, 20, 2081-2090.	2.9	14
12	A Photoprotein in Mouse Embryonic Stem Cells Measures Ca2+ Mobilization in Cells and in Animals. PLoS ONE, 2010, 5, e8882.	2.5	12
13	Regulation of cholesterol/lipid biosynthetic genes by Egr2/Krox20 during peripheral nerve myelination. Journal of Neurochemistry, 2005, 93, 737-748.	3.9	83
14	Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. Neurobiology of Aging, 2003, 24, 927-931.	3.1	75
15	IL-1 genes in myasthenia gravis: IL-1A â^889 polymorphism associated with sex and age of disease onset. Journal of Neuroimmunology, 2002, 122, 94-99.	2.3	22
16	Prion protein gene polymorphism and Alzheimer's disease: one modulatory trait of cognitive decline?. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 71, 279-280.	1.9	28
17	Association of early-onset Alzheimer's disease with an interleukin-1? gene polymorphism. Annals of Neurology, 2000, 47, 361-365.	5.3	358
18	Gene polymorphism affecting $\hat{l}\pm 1$ -antichymotrypsin and interleukin-1 plasma levels increases Alzheimer's disease risk. Annals of Neurology, 2000, 48, 388-391.	5. 3	114

#	Article	IF	CITATION
19	Increased plasma levels of interleukin-1, interleukin-6 and $\hat{l}\pm 1$ -antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. Journal of Neuroimmunology, 2000, 103, 97-102.	2.3	379
20	Association study of a new polymorphism in the PECAM-1 gene in multiple sclerosis. Journal of Neuroimmunology, 2000, 104, 174-178.	2.3	19
21	Lack of association between IL-1A and IL-1B promoter polymorphisms and multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2000, 69, 564-565.	1.9	17
22	Gene polymorphism affecting α1â€antichymotrypsin and interleukinâ€1 plasma levels increases Alzheimer's disease risk. Annals of Neurology, 2000, 48, 388-391.	5. 3	5
23	APOE Îμ2-4 and -491 polymorphisms are not associated with MS. Neurology, 1999, 53, 888-888.	1.1	43
24	Apolipoprotein E and \hat{l} ±-1-antichymotrypsin allele polymorphism in sporadic and familial Alzheimer's disease. Neuroscience Letters, 1999, 270, 129-132.	2.1	42
25	<i>APOE Ⱂ491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease</i> Neurology, 1999, 53, 1888-1888.	1.1	33
26	Adenosine A _{2A} Receptors and Neuroprotection. Annals of the New York Academy of Sciences, 1997, 825, 30-48.	3.8	99